Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

SGLT2 inhibitors after acute kidney injury to improve outcomes in type 2 diabetes

Award Number: K23DK144716
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 07/15/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2030

Group Awards By:

View Award Description

SGLT2 inhibitors after acute kidney injury to improve outcomes in type 2 diabetes - PROJECT SUMMARY / ABSTRACT The safe and effective ways to care for patients after acute kidney injury (AKI) is a significant unknown in the medical field and one of growing attention. There is significant uncertainty about use of kidney-protecting medications in patients who have had AKI because many of those medications, paradoxically, reduce kidney function when initiated or resumed before their kidney-protecting qualities become apparent. This leads to deferral of therapy for many patients who have had recent AKI and other risk-factors, like chronic kidney disease (CKD) and diabetes mellitus. These patients are actually at heightened risk for multiple adverse outcomes that kidney-protecting medications prevent. Such deferrals may even become indefinite. The newest of these medication classes being impacted by these post-AKI practices are sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are first-line therapy for type 2 diabetes and are known to prevent progression of CKD and cardiovascular events. Observational studies, including those published by the applicant Dr. Daniel Murphy, show favorable outcomes when SGLT2 inhibitors are provided after AKI to those with type 2 diabetes. Now Dr. Murphy seeks to translate these findings into a pilot, pragmatic, cluster-randomized clinical trial (RCT) based in primary care clinics to demonstrate the feasibility of an intervention to increase use of SGLT2 inhibitors after AKI (Aim 1). Nested within the pilot RCT, Dr. Murphy seeks to conduct a qualitative study focused on the experience of primary care providers and pharmacists and, separately, patients, within the pilot RCT. These interviews will identify barriers to prescribing, receiving, and taking a SGLT2 inhibitor and the perceived impact of our study’s intervention, which will help Dr. Murphy craft changes to the study intervention for designing a future RCT based on all his K23 results (Aim 2). In parallel with these efforts, Dr. Murphy will use electronic health record-data from patients with type 2 diabetes and AKI to determine predictors of SGLT2 inhibitor receipt, which could be used in identifying patients to recruit for a future RCT after this pilot study (Aim 3). Paired with applicable training, these research questions in this K23 Mentored Patient-Oriented Research Career Development Award will position Dr. Murphy as an independent clinical researcher equipped in both pragmatic RCT design and conduct alongside his skillset in using observational data to identify potential treatments and strategies that may improve clinical outcomes. His career will include investigating treatments to care for patients who have suffered AKI though observational and interventional means.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $166,953 )
2025	2025	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	7/15/2025	NEW	$166,953
														Subtotal = $166,953

Grand Total All Awards = $166,953

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SGLT2 inhibitors after acute kidney injury to improve outcomes in type 2 diabetes

Award Number: K23DK144716

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 07/15/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer